Albinterferon Alfa-2B

Identification

Generic Name
Albinterferon Alfa-2B
DrugBank Accession Number
DB05396
Background

Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Interferons
Protein Chemical Formula
C3796H5937N1015O1143S50
Protein Average Weight
85700.0 Da
Sequences
Not Available
Synonyms
  • alb-IFN
  • Albinterferon
  • Albinterferon Alfa-2B
  • Albuferon alpha
  • Albumin-interferon alpha

Pharmacology

Indication

Investigated for use/treatment in hepatitis (viral, C).

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Interferons belong to a family of proteins known as cytokines that occur naturally in the human body. Cytokines control cellular processes, such as cell growth, activation, migration and aging. While the precise mechanism of action for interferon alpha is not known, research has demonstrated direct antiviral activity in patients with diseases like hepatitis C, as well as immune-modulating and direct antitumor effects in certain types of cancer.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Albinterferon Alfa-2B.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Albinterferon Alfa-2B.
AcyclovirThe metabolism of Acyclovir can be decreased when combined with Albinterferon Alfa-2B.
AgomelatineThe metabolism of Agomelatine can be decreased when combined with Albinterferon Alfa-2B.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Albinterferon Alfa-2B.
AlosetronThe metabolism of Alosetron can be decreased when combined with Albinterferon Alfa-2B.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Albinterferon Alfa-2B.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Albinterferon Alfa-2B.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Albinterferon Alfa-2B.
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Albinterferon Alfa-2B.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Albuferon

Categories

ATC Codes
L03AB12 — Albinterferon alfa-2b
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
4DVS4AG4DF
CAS number
472960-22-8

References

General References
  1. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C: Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther. 2002 Nov;303(2):540-8. [Article]
PubChem Substance
347910117
Wikipedia
Albinterferon

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection2
2CompletedTreatmentHepatitis C Viral Infection1
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1CompletedTreatmentHepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections1
1, 2TerminatedTreatmentHepatitis B Chronic Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Delaporte E, Renton KW: Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcriptional and post-transcriptional levels by conditions resulting in interferon-alpha/beta induction. Life Sci. 1997;60(10):787-96. doi: 10.1016/s0024-3205(97)00006-4. [Article]

Drug created on November 18, 2007 18:24 / Updated on February 21, 2021 18:51